ASH 2023 | The addition of immunotherapy to the front-line treatment of AS Hodgkin lymphoma
Carla Casulo, MD, University of Rochester Medical Center-Wilmot Cancer Institute, Rochester, NY, discusses the addition of immunotherapy to the front-line treatment of patients with advanced-stage (AS) Hodgkin lymphoma (HL). The SWOG S1826 trial (NCT03907488), conducted by the US National Clinical Trials Network, investigated the addition of brentuximab vedotin or nivolumab to the standard of care AVD chemotherapy regimen (doxorubicin, vinblastine, and dacarbazine). Subset analyses of pediatric patients and patients over the age of 60 were presented at the ASH 2023 meeting, and Dr Casulo believes that the findings will result in changes to the standard of care for these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: SecuraBio, GenMab, Bristol Myers Squibb, Gilead Sciences, Verastem, Genentech
Consultancy: Abbvie, Bristol Myers Squibb, Genentech
Leadership role: Follicular Lymphoma Foundation, Lymphoma Research Foundation
